For laboratory research use only. This page summarises published scientific literature on CJC-1295 in plain English, in a neutral research style. It is not medical advice and contains no guidance on doses, administration or human use.

CJC-1295 UK: Complete Research Guide (2026)

Research Disclaimer: CJC-1295 is sold for research and laboratory purposes only. It is not approved for human consumption and should not be used outside of controlled research settings. All information presented here is for educational purposes only.

What is CJC-1295?

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), a naturally occurring peptide hormone that regulates the synthesis and secretion of growth hormone from the anterior pituitary gland. As a GHRH analogue, CJC-1295 directly stimulates GHRH receptors in the pituitary, triggering the release of GH into circulation. The compound was developed through peptide engineering to improve upon the pharmacokinetic properties of native GHRH, which has a very short half-life and limited duration of action.

CJC-1295 is a 30-amino acid peptide that retains the critical GHRH-receptor-binding domain of native GHRH whilst incorporating structural modifications that enhance its stability and extend its biological activity. These modifications make CJC-1295 a valuable research tool for investigating GH physiology, metabolic regulation, and the long-term effects of enhanced GH signalling. The compound exists in two primary variants: CJC-1295 with DAC and CJC-1295 without DAC, each with distinct pharmacokinetic profiles and research applications.

Mechanism of Action: GHRH Analogue Function

CJC-1295 operates through direct activation of GHRH receptors located on somatotroph cells in the anterior pituitary gland. The GHRH receptor is a G-protein-coupled receptor (GPCR) that, when activated, triggers intracellular signalling cascades leading to the synthesis and secretion of growth hormone. Unlike growth hormone secretagogues such as Ipamorelin, which work through the ghrelin receptor (GHS-R1a), CJC-1295 works through a distinct GHRH receptor pathway.

The biological significance of this mechanism is that CJC-1295 stimulates GH release through the same receptor system that native GHRH activates, making it highly physiologically relevant for research purposes. The GHRH receptor pathway is one of the two primary positive regulators of GH secretion (the other being the ghrelin pathway), and research with CJC-1295 allows investigators to study the specific role of GHRH signalling in GH physiology without the confounding effects of other hormonal systems.

CJC-1295 with DAC vs Without DAC: Pharmacokinetic Differences

The two primary variants of CJC-1295 differ fundamentally in their pharmacokinetics and duration of action, making them suitable for different research applications.

CJC-1295 with DAC (Drug Affinity Complex): The DAC is a carrier moiety composed of collagen-binding domain sequences that extend the half-life of CJC-1295 dramatically. In research settings, CJC-1295 with DAC exhibits a circulating half-life of approximately 7-8 days, compared to the much shorter half-life of unmodified CJC-1295. This extended half-life is achieved because the DAC facilitates binding of CJC-1295 to serum albumin and other blood proteins, reducing renal clearance and extending the duration of the compound in circulation.

From a research design perspective, the choice between CJC-1295 with DAC and without DAC depends on whether the study objective is to investigate sustained GH elevation (favouring the DAC variant) or acute pulsatile GH secretion (favouring the non-DAC variant).

UK Legal Status

CJC-1295 is not approved as a pharmaceutical medication in the United Kingdom. It is classified as a research chemical and is legally available for purchase through licensed research suppliers for legitimate research and laboratory purposes. The compound is not controlled under the Misuse of Drugs Act, though it is subject to regulations governing research chemicals and peptides.

All suppliers in the UK must ensure that CJC-1295 is sold with appropriate labelling stating its research-only status and explicitly indicating that it is not approved for human consumption. Researchers and institutions must purchase CJC-1295 through reputable, licensed suppliers and maintain proper documentation of its use for research purposes.

UK Sourcing and Quality Standards

Quality indicators to evaluate include: third-party laboratory verification of purity and amino acid sequence accuracy, documentation of manufacturer identity and GMP (Good Manufacturing Practice) certification, proper storage and handling conditions, and transparent pricing. Establishing relationships with trusted UK-based suppliers ensures consistent product quality and regulatory compliance across research projects.

2026 update: the CJC-1295 + Ipamorelin pairing

Limits of the evidence

Published findings come from specific study designs, often in cell systems or animals, and do not transfer automatically to other settings. A paper about a molecule is not proof that any particular batch has a given biological effect. Purity data show what is in a vial; they do not show sterility, safety or suitability for any use outside the laboratory.

Laboratory handling

Store lyophilised powder sealed, cold (−20 °C for long-term storage), dry and protected from light.
Let vials reach room temperature before opening to limit condensation.
Prepare solutions with suitable laboratory solvents and calibrated equipment, and label each with lot number, concentration and date.
Split solutions into single-use aliquots and avoid repeated freeze–thaw cycles.
Use the peptide calculator for concentration arithmetic (mg/mL).

For laboratory research use only. CJC-1295 sold by Peptides Lab UK is supplied strictly for in vitro laboratory research. It is not for human or veterinary use, and nothing on this page is medical advice or guidance on administration. UK purchasers are responsible for complying with all applicable legislation.

CJC-1295 UK: Complete Research Guide (2026)